Where does Carlos Paya work?

Carlos Paya is Venture Partner at Abingworth.

What does Carlos Paya invest in?

Carlos Paya invests in Biotech.

Where did Carlos Paya go to school?

Carlos Paya studied at The University of Chicago Booth School of Business (CEI, Executive Business Education); Institute Pasteur, Paris, France (Postdoctoral training, Viral Immunology); Mayo Clinic Alix School of Medicine (Fellowship, Infectious Diseases and Immunology).

Carlos Paya

Investor

Venture Partner at Abingworth · Venture Partner at Ysios Capital

Seattle, Washington, United States

Find your path to Carlos

381 people in our graph share verified history with Carlos — schools, employers, funds. One of them is your warm intro.

René KuijtenunlockedCarlos: together at Mayo Clinic Alix School of Medicine (1989)

×2Carlos: together at The University of Chicago Booth School of Business

Carlos: together at Imu Biosciences

×4Carlos: together at Universidad Complutense de Madrid

About

Dr. Carlos Paya has held leadership roles across academic medicine, large pharmaceutical companies, and biotech startups, focusing on strategic execution, pipeline growth, product lifecycle management, and fundraising. He previously served as president and CEO of Immune Design Corp. until its 2019 acquisition by Merck, and held senior roles at Elan Pharmaceuticals and Eli Lilly. Earlier in his career he spent nearly a decade at the Mayo Clinic-Rochester as a professor of medicine, immunology, and pathology and vice dean of its clinical investigation program.

Contact· self-published, not guessed

s•••@ysioscapital.comreveal

Invests in

Biotech

Experience

Collegium Pharmaceutical, Inc.Board Membercurrent2025 — presentBoston, Massachusetts, United States
IMU BiosciencesBoard Membercurrent2025 — presentLondon Area, United Kingdom
VaxcyteChairman of the Boardcurrent2022 — presentSan Francisco, California, United States
Highlight Therapeutics SLChairperson of the Boardcurrent2020 — presentMadrid, Spain
AbingworthVenture Partnercurrent2020 — present
Fluidigm Standard BiotoolsChairman of the Board2017 — 2024San Francisco, California, United States
MallinkrodtBoard Member2019 — 2022Dublin, County Dublin, Ireland
Immune Design CorpPresident and CEO2011 — 2019Seattle, WA
Elan PharmaceuticalsPresident2008 — 2011San Francisco Bay Area
Eli LillyVP2001 — 2008
Mayo ClinicProfessor of Medicine and Immunology1991 — 2001

Skills & more

Medical Devices3Biopharmaceuticals8GCP4Infectious Diseases18Technology Transfer4Lifesciences9Biotechnology29Neuroscience3Drug Development12Immunology36Regulatory Affairs3Oncology16

+12 more

Clinical DevelopmentClinical ResearchClinical TrialsCardiologyMolecular BiologyNeurologyDrug DiscoveryDiabetesRCTMSINDPharmaceutical Industry

From Carlos's professional profile.

Investments

Board seats

FluidigmFluidigm CorporationHighlight TherapeuticsMallinckrodtMallinckrodt Pharmaceuticals

Per the firm's website.

Colleagues at Abingworth

Alex Asquith

Counsel at Abingworth

Amit Khasgiwala

Investment Professional at Innovatus Capital Partners

Andrew Sinclair

Managing Director, Head of Publics & Late Stage at Abingworth

Ankur Shah

Vice President, CCD at Abingworth

Anna Slezak

Senior Associate at Abingworth

Bali Muralidhar

Global Head of Life Sciences & CIO at Abingworth

David Leathers

General Partner at Abingworth

Dayle Hogg

Operating Executive at Abingworth

Frequently asked questions

Who is Carlos Paya?: Dr. Carlos Paya has held leadership roles across academic medicine, large pharmaceutical companies, and biotech startups, focusing on strategic execution, pipeline growth, product lifecycle management, and fundraising. He previously served as president and CEO of Immune Design Corp. until its 2019 acquisition by Merck, and held senior roles at Elan Pharmaceuticals and Eli Lilly. Earlier in his career he spent nearly a decade at the Mayo Clinic-Rochester as a professor of medicine, immunology, and pathology and vice dean of its clinical investigation program.
Where does Carlos Paya work?: Carlos Paya is Venture Partner at Abingworth.
What does Carlos Paya invest in?: Carlos Paya invests in Biotech.
What boards does Carlos Paya sit on?: Carlos Paya holds tracked board seats at Fluidigm, Fluidigm Corporation, Highlight Therapeutics, Mallinckrodt, Mallinckrodt Pharmaceuticals.
Where did Carlos Paya go to school?: Carlos Paya studied at The University of Chicago Booth School of Business (CEI, Executive Business Education); Institute Pasteur, Paris, France (Postdoctoral training, Viral Immunology); Mayo Clinic Alix School of Medicine (Fellowship, Infectious Diseases and Immunology).